Unlock Cutting-Edge Opportunities at Innate Pharma’s June 2023 Investor Conferences

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) is pleased to announce that members of its senior management team will be speaking at a series of upcoming conferences. Don’t miss out on this opportunity to gain insight into the company’s progress and plans for the future!

Unveiling Breakthrough Cancer Treatments at ASCO 2023: A Look Ahead

Unlocking the Secrets of the Healthcare Industry: Attending the 2023 Jefferies Healthcare Conference

Unlock Opportunities at Goldman Sachs’ 44th Annual Global Healthcare Conference!

Exploring the Future of European Healthcare: Stifel European Healthcare Summit 2023

About Innate Pharma

Innate Pharma S.A. is on a mission to revolutionize the clinical treatment of cancer patients with its innovative immunotherapies. Through its ANKET® (Antibody-based NK cell Engager Therapeutics) platform, the company aims to activate the patient’s own innate immune system to fight cancer cells. With an ambitious vision, Innate Pharma S.A. is committed to saving and improving the lives of cancer patients around the world.

Innate’s impressive portfolio encompasses lacutamab, a cutting-edge, proprietary program for treating advanced cases of cutaneous T cell lymphomas and peripheral T cell lymphomas, as well as monalizumab, co-developed with AstraZeneca for non-small cell lung cancer. Additionally, ANKET® multi-specific NK cell engagers promise effective treatment for multiple tumor types.

Innate Pharma is a biopharmaceutical powerhouse, forging strategic partnerships with major industry players such as Sanofi and AstraZeneca to push the boundaries of medical discovery. With the ultimate goal of improving and streamlining the development of treatments for patients worldwide, they have committed themselves to driving progress and innovating the world of medical research.

Innate Pharma, a pioneering biopharmaceutical company, has set up its headquarters in Marseille, France and a U.S. office in Rockville, MD, to consistently serve their international customer base. With presence on Euronext Paris and Nasdaq markets, this forward-thinking company is constantly pushing the boundaries of what’s possible in healthcare.

Disclaimer on forward-looking information and risk factors

At Innate Pharma, we are well-positioned to make strides in research and development that could have a significant impact on our growth and the healthcare industry. We are committed to developing and commercializing our product candidates with a special focus on safety, clinical trials and regulatory approvals.

However, there are certain risks and uncertainties that could affect our progress. These may include our ability to raise capital, delays or setbacks in clinical trials, and changes in regulatory requirements. We are taking steps to mitigate these risks and remain confident that our plans will yield successful outcomes.

Innate Pharma is inviting investors to take advantage of an exciting opportunity! Don’t miss out on the chance to own a piece of this promising company. This offer is available in all countries, so don’t delay – act now to secure your investment today.

Leave a Comment